組織工程皮膚替代品市場：規模、細分、份額、法規、報銷、程序、到 2033 年的預測

組織工程皮膚替代品的使用提供了一種治療慢性傷口的替代療法，與傳統療法相比，它顯示出卓越的功效，在某些情況下，成本效益相當。 其主要目標是利用功能結構最終修復、維持和改善受損的組織和器官，改善恢復過程和生存機會。

組織工程皮膚替代品是彌補捐贈者皮膚移植供應短缺的有效方法。 這種皮膚替代品可以保護受傷部位免受液體流失和污染，促進傷口部位細胞激素和生長因子的釋放，加速傷口癒合過程。 它還為正在癒合的傷口床提供臨時保護。

表皮傷口癒合延遲會為患者的健康帶來多種風險，包括死亡。 從更深層次來說，還存在形成嚴重慢性傷口的風險。 皮膚替代品透過提供必要的細胞、可溶性介質和細胞外基質材料來促進癒合，有望使頑固性傷口恢復。 在美國，慢性傷口護理每年平均花費約 320 億美元。 這些慢性傷口90%是由糖尿病、靜脈瘀血、放射線、癱瘓等造成的。

本報告深入探討了全球組織工程皮膚替代品市場，包括競爭格局、SWOT 分析、到 2033 年的市場預測、COVID-19 的影響、區域和國家趨勢等。

目錄

目前市面上的組織工程皮膚替代品及競爭狀況

• 對主要產業趨勢的見解
• 2015 年至 2033 年組織工程皮膚替代品按細分市場劃分的市場總收入和市場前景
• 有關數量、平均售價和市場價值的詳細數據

全球、區域與國家見解

• 組織工程皮膚替代品市場的SWOT分析
• 組織工程皮膚替代品市場的競爭動態洞察與趨勢
• 各國醫療保健系統概覽
• 按國家/地區劃分的報銷政策
• 各國醫療科技的監管狀況

Abstract

Tissue Engineered - Skin Substitutes Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within Wound Care Management therapeutic area.

The model discusses in detail the impact of COVID-19 on Tissue Engineered - Skin Substitutes market for the year 2020 and beyond. The use of skin substitutes provides an alternative therapy to heal chronic wounds showing superior efficacy and, in some cases, similar cost-effectiveness compared to traditional treatments. The main objective is to make use of functional construct that can ultimately restore, maintain and improve damaged tissues and organs through improving the recovery process and chances of survival.

Tissue-engineered skin substitutes represent an efficient way of meeting the deficiency in donor-skin-graft supplies. They are able to protect damaged regions from fluid loss and contamination and promote release of cytokines and growth factors at the wound site, accelerating the wound-healing processes. They also act as a temporary protective cover of the wound bed during healing.

Epidermal wounds which show delayed healing process can lead to several risks to patient's health including death. A deeper level risk of these can lead to serious chronic wound formation. Skin substitutes have lead to promising recovery practices for refractory wounds by providing cells, soluble mediators, and extracellular matrix materials needed to stimulate healing. On average, it is observed that the cost spent for chronic wound treatments comes to around $32B in the US annually. 90% of these chronic wounds are a result of diabetes, venous stasis, radiation or paralysis.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Tissue Engineered - Skin Substitutes and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total Tissue Engineered - Skin Substitutes market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Tissue Engineered - Skin Substitutes market.
• Competitive dynamics insights and trends provided for Tissue Engineered - Skin Substitutes market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered - Integra LifeSciences Corp, LifeNet Health Inc, MiMedx Group Inc, Organogenesis Holdings Inc, Smith & Nephew Plc, Allergan Ltd, and Others.

Countries covered - United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Tissue Engineered - Skin Substitutes marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Tissue Engineered - Skin Substitutes market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Tissue Engineered - Skin Substitutes market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Tissue Engineered - Skin Substitutes market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Tissue Engineered - Skin Substitutes market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.